<p>Royce &amp; Associates LP 在第三季度收購了 Tandem Diabetes Care, Inc. (NASDAQ:TNDM - 免費報告) 的新頭寸，根據其最近向證券交易委員會提交的 13F 表格。該機構投資者收購了 510,000 股該醫療設備公司的股票，價值約為 6,191,000 美元。Royce &amp; Associates LP 在最近的報告期末持有 Tandem Diabetes Care 約 0.75% 的股份。</p>
<p>獲取 <strong>Tandem Diabetes Care</strong> 警報：</p>
<p>其他機構投資者和對沖基金最近也調整了對該公司的持股。Amalgamated Bank 在第三季度將其在 Tandem Diabetes Care 的持股增加了 3.5%。Amalgamated Bank 現在擁有 19,617 股該醫療設備公司的股票，價值 238,000 美元，在此期間又購買了 657 股。賓夕法尼亞州公共學校僱員退休系統在第二季度將其在 Tandem Diabetes Care 的股份增加了 8.8%。賓夕法尼亞州公共學校僱員退休系統現在擁有 17,101 股該醫療設備公司的股票，價值 319,000 美元，在上個季度又購買了 1,384 股。新澤西州警察和消防員退休系統在第二季度將其在 Tandem Diabetes Care 的持股增加了 10.1%。新澤西州警察和消防員退休系統現在擁有 15,299 股該醫療設備公司的股票，價值 285,000 美元，在上個季度又購買了 1,399 股。PNC Financial Services Group Inc. 在第二季度將其在 Tandem Diabetes Care 的股份增加了 8.9%。PNC Financial Services Group Inc. 現在擁有 20,954 股該醫療設備公司的股票，價值 391,000 美元，在上個季度又收購了 1,719 股。最後，Diversified Trust Co 在第三季度將其在 Tandem Diabetes Care 的股份增加了 12.2%。Diversified Trust Co 現在擁有 18,339 股該醫療設備公司的股票，價值 223,000 美元，在上個季度又收購了 1,991 股。</p>
<h2>Tandem Diabetes Care 股價下跌 1.4%</h2>
<p>週四，TNDM 的開盤價為 23.41 美元。該公司的速動比率為 2.02，流動比率為 2.55，債務與股本比率為 2.00。該股票的 50 天移動平均線為 21.42 美元，200 天移動平均線為 17.82 美元。該公司的市值為 16 億美元，市盈率為 -7.63，貝塔值為 1.63。Tandem Diabetes Care, Inc. 的 52 周低點為 9.98 美元，52 周高點為 29.65 美元。</p>
<p>Tandem Diabetes Care (NASDAQ:TNDM - 獲取免費報告) 最近於 2 月 19 日（星期四）公佈了季度財報。該醫療設備公司報告本季度每股收益為（0.01）美元，超出市場共識預期的（0.05）美元 0.04 美元。該公司本季度的收入為 2.9038 億美元，而分析師預期為 2.7714 億美元。Tandem Diabetes Care 的淨利潤率為 -20.17%，股本回報率為 -68.23%。與去年同期相比，該公司的收入增長了 15.1%。在去年同期，該公司每股收益為 0.01 美元。分析師預測，Tandem Diabetes Care, Inc. 今年的每股收益將為 -1.68 美元。</p>
<h2>分析師設定新目標價</h2>
<p>TNDM 已成為多份研究報告的主題。巴克萊在 2 月 23 日（星期一）的研究報告中重申了 &#34;增持&#34; 評級，並將 Tandem Diabetes Care 的目標價設定為 56.00 美元。Sanford C. Bernstein 在 1 月 9 日（星期五）的研究報告中重申了 &#34;市場表現&#34; 評級，並將 Tandem Diabetes Care 的目標價設定為 25.00 美元（上調自 18.00 美元）。瑞穗在 2 月 20 日（星期五）的研究報告中將 Tandem Diabetes Care 的目標價設定為 22.00 美元，並給予該股票 &#34;中性&#34; 評級。Lake Street Capital 在 2 月 23 日（星期一）的研究報告中將 Tandem Diabetes Care 的評級從 &#34;持有&#34; 上調至 &#34;買入&#34;，並將目標價設定為 50.00 美元。最後，瑞銀集團在 2 月 20 日（星期五）的報告中重申了 &#34;中性&#34; 評級，並將 Tandem Diabetes Care 的目標價設定為 22.00 美元（上調自 17.00 美元）。一位投資分析師對該股票給予了強烈買入評級，六位分析師給予了買入評級，十一位分析師給予了持有評級，一位分析師給予了賣出評級。根據 MarketBeat.com 的數據，該股票的共識評級為 &#34;持有&#34;，共識目標價為 28.11 美元。</p>
<p><strong>獲取我們最新的 Tandem Diabetes Care 股票報告</strong></p>
<h2>Tandem Diabetes Care 公司簡介</h2>
<p>（免費報告）</p>
<p>Tandem Diabetes Care, Inc NASDAQ: TNDM，總部位於加利福尼亞州聖地亞哥，是一家醫療設備公司，專注於為胰島素依賴型糖尿病患者設計、開發和商業化創新的胰島素輸送系統。公司成立於 2006 年，2011 年推出了首款產品 t:slim® 胰島素泵，並自此建立了一個包含觸摸屏界面、遠程軟件更新和集成連續血糖監測（CGM）功能的下一代泵的產品組合。</p>
<p>該公司的旗艦產品 t:slim X2® 胰島素泵，旨在與領先的 CGM 傳感器配合使用，並具有根據實時血糖趨勢調整基礎胰島素速率的自動胰島素輸送算法。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們更看好的股票比 Tandem Diabetes Care 更好</li>
<li>華爾街害怕的黃金圖表……</li>
<li>美國的 1776 再次發生</li>
<li>在 2026 年 5 月之前購買這隻黃金股票</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
<li>用這 4 個簡單步驟 &#34;防止美聯儲影響&#34; 你的銀行賬户</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5ETQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5ETQ"/></p>
<p><em>此即時新聞警報由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 $1,000 在 Tandem Diabetes Care 嗎？</h2>
<p>在考慮 Tandem Diabetes Care 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及他們推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Tandem Diabetes Care 並不在名單上。</p>
<p>雖然分析師目前對 Tandem Diabetes Care 的評級為持有，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

醫藥突破 ETF - ALPS

標普健康醫療設備 ETF - SPDR

紐交所高增長板生物技術指數 ETF - First Trust

動態生物技術與基因組 ETF - Invesco

2 倍做多納斯達克生物技術 ETF - ProShares

美國醫藥設備 ETF - iShares

標普生物技術 ETF - SPDR

納斯達克生物科技指數 ETF - iShares Nasdaq

生物科技 ETF - VanEck Vectors

TNDM

<p>Royce & Associates LP 已在 Tandem Diabetes Care, Inc. (NASDAQ:TNDM) 中獲得了一個新頭寸，購買了 510,000 股，價值約為 619 萬美元。這項投資佔公司總股份的約 0.75%。其他機構投資者也增加了在 Tandem 的持股。該股票開盤價為 23.41 美元，市值為 16 億美元，市盈率為 -7.63。分析師設定了不同的目標價格，普遍評級為 “持有”，目標價格為 28.11 美元</p>

<p>Royce &amp; Associates LP acquired a new position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities &amp; Exchange Commission. The institutional investor acquired 510,000 shares of the medical device company's stock, valued at approximately $6,191,000. Royce &amp; Associates LP owned approximately 0.75% of Tandem Diabetes Care at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Royce &amp; Associates LP 在第三季度收購了 Tandem Diabetes Care, Inc. (NASDAQ:TNDM - 免費報告) 的新頭寸，根據其最近向證券交易委員會提交的 13F 表格。該機構投資者收購了 510,000 股該醫療設備公司的股票，價值約為 6,191,000 美元。Royce &amp; Associates LP 在最近的報告期末持有 Tandem Diabetes Care 約 0.75% 的股份。</p>
</div><p>Get <strong>Tandem Diabetes Care</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Tandem Diabetes Care</strong> 警報：</p>
</div><p>Other institutional investors and hedge funds have also recently modified their holdings of the company. Amalgamated Bank boosted its holdings in Tandem Diabetes Care by 3.5% in the 3rd quarter. Amalgamated Bank now owns 19,617 shares of the medical device company's stock worth $238,000 after buying an additional 657 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in Tandem Diabetes Care by 8.8% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 17,101 shares of the medical device company's stock valued at $319,000 after buying an additional 1,384 shares during the last quarter. Police &amp; Firemen s Retirement System of New Jersey grew its holdings in Tandem Diabetes Care by 10.1% during the 2nd quarter. Police &amp; Firemen s Retirement System of New Jersey now owns 15,299 shares of the medical device company's stock valued at $285,000 after buying an additional 1,399 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in Tandem Diabetes Care by 8.9% in the 2nd quarter. PNC Financial Services Group Inc. now owns 20,954 shares of the medical device company's stock worth $391,000 after acquiring an additional 1,719 shares during the last quarter. Finally, Diversified Trust Co increased its stake in Tandem Diabetes Care by 12.2% in the 3rd quarter. Diversified Trust Co now owns 18,339 shares of the medical device company's stock worth $223,000 after acquiring an additional 1,991 shares during the last quarter.</p>
<div class="lb-trans"><p>其他機構投資者和對沖基金最近也調整了對該公司的持股。Amalgamated Bank 在第三季度將其在 Tandem Diabetes Care 的持股增加了 3.5%。Amalgamated Bank 現在擁有 19,617 股該醫療設備公司的股票，價值 238,000 美元，在此期間又購買了 657 股。賓夕法尼亞州公共學校僱員退休系統在第二季度將其在 Tandem Diabetes Care 的股份增加了 8.8%。賓夕法尼亞州公共學校僱員退休系統現在擁有 17,101 股該醫療設備公司的股票，價值 319,000 美元，在上個季度又購買了 1,384 股。新澤西州警察和消防員退休系統在第二季度將其在 Tandem Diabetes Care 的持股增加了 10.1%。新澤西州警察和消防員退休系統現在擁有 15,299 股該醫療設備公司的股票，價值 285,000 美元，在上個季度又購買了 1,399 股。PNC Financial Services Group Inc. 在第二季度將其在 Tandem Diabetes Care 的股份增加了 8.9%。PNC Financial Services Group Inc. 現在擁有 20,954 股該醫療設備公司的股票，價值 391,000 美元，在上個季度又收購了 1,719 股。最後，Diversified Trust Co 在第三季度將其在 Tandem Diabetes Care 的股份增加了 12.2%。Diversified Trust Co 現在擁有 18,339 股該醫療設備公司的股票，價值 223,000 美元，在上個季度又收購了 1,991 股。</p>
</div><h2>Tandem Diabetes Care Trading Down 1.4%</h2>
<div class="lb-trans"><h2>Tandem Diabetes Care 股價下跌 1.4%</h2>
</div><p>TNDM opened at $23.41 on Thursday. The company has a quick ratio of 2.02, a current ratio of 2.55 and a debt-to-equity ratio of 2.00. The stock's fifty day moving average is $21.42 and its two-hundred day moving average is $17.82. The company has a market capitalization of $1.60 billion, a P/E ratio of -7.63 and a beta of 1.63. Tandem Diabetes Care, Inc. has a 52 week low of $9.98 and a 52 week high of $29.65.</p>
<div class="lb-trans"><p>週四，TNDM 的開盤價為 23.41 美元。該公司的速動比率為 2.02，流動比率為 2.55，債務與股本比率為 2.00。該股票的 50 天移動平均線為 21.42 美元，200 天移動平均線為 17.82 美元。該公司的市值為 16 億美元，市盈率為 -7.63，貝塔值為 1.63。Tandem Diabetes Care, Inc. 的 52 周低點為 9.98 美元，52 周高點為 29.65 美元。</p>
</div><p>Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last announced its quarterly earnings results on Thursday, February 19th. The medical device company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.04. The firm had revenue of $290.38 million during the quarter, compared to analysts' expectations of $277.14 million. Tandem Diabetes Care had a negative net margin of 20.17% and a negative return on equity of 68.23%. The company's revenue was up 15.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.01 EPS. Analysts forecast that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current year.</p>
<div class="lb-trans"><p>Tandem Diabetes Care (NASDAQ:TNDM - 獲取免費報告) 最近於 2 月 19 日（星期四）公佈了季度財報。該醫療設備公司報告本季度每股收益為（0.01）美元，超出市場共識預期的（0.05）美元 0.04 美元。該公司本季度的收入為 2.9038 億美元，而分析師預期為 2.7714 億美元。Tandem Diabetes Care 的淨利潤率為 -20.17%，股本回報率為 -68.23%。與去年同期相比，該公司的收入增長了 15.1%。在去年同期，該公司每股收益為 0.01 美元。分析師預測，Tandem Diabetes Care, Inc. 今年的每股收益將為 -1.68 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>TNDM has been the subject of a number of research reports. Barclays reiterated an &#34;overweight&#34; rating and set a $56.00 target price on shares of Tandem Diabetes Care in a research report on Monday, February 23rd. Sanford C. Bernstein reiterated a &#34;market perform&#34; rating and set a $25.00 price objective (up from $18.00) on shares of Tandem Diabetes Care in a research report on Friday, January 9th. Mizuho set a $22.00 price objective on shares of Tandem Diabetes Care and gave the stock a &#34;neutral&#34; rating in a research note on Friday, February 20th. Lake Street Capital upgraded shares of Tandem Diabetes Care from a &#34;hold&#34; rating to a &#34;buy&#34; rating and set a $50.00 target price on the stock in a research report on Monday, February 23rd. Finally, UBS Group reaffirmed a &#34;neutral&#34; rating and issued a $22.00 price target (up from $17.00) on shares of Tandem Diabetes Care in a report on Friday, February 20th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of &#34;Hold&#34; and a consensus price target of $28.11.</p>
<div class="lb-trans"><p>TNDM 已成為多份研究報告的主題。巴克萊在 2 月 23 日（星期一）的研究報告中重申了 &#34;增持&#34; 評級，並將 Tandem Diabetes Care 的目標價設定為 56.00 美元。Sanford C. Bernstein 在 1 月 9 日（星期五）的研究報告中重申了 &#34;市場表現&#34; 評級，並將 Tandem Diabetes Care 的目標價設定為 25.00 美元（上調自 18.00 美元）。瑞穗在 2 月 20 日（星期五）的研究報告中將 Tandem Diabetes Care 的目標價設定為 22.00 美元，並給予該股票 &#34;中性&#34; 評級。Lake Street Capital 在 2 月 23 日（星期一）的研究報告中將 Tandem Diabetes Care 的評級從 &#34;持有&#34; 上調至 &#34;買入&#34;，並將目標價設定為 50.00 美元。最後，瑞銀集團在 2 月 20 日（星期五）的報告中重申了 &#34;中性&#34; 評級，並將 Tandem Diabetes Care 的目標價設定為 22.00 美元（上調自 17.00 美元）。一位投資分析師對該股票給予了強烈買入評級，六位分析師給予了買入評級，十一位分析師給予了持有評級，一位分析師給予了賣出評級。根據 MarketBeat.com 的數據，該股票的共識評級為 &#34;持有&#34;，共識目標價為 28.11 美元。</p>
</div><p><strong>Get Our Latest Stock Report on Tandem Diabetes Care</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 Tandem Diabetes Care 股票報告</strong></p>
</div><h2>Tandem Diabetes Care Profile</h2>
<div class="lb-trans"><h2>Tandem Diabetes Care 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Tandem Diabetes Care, Inc NASDAQ: TNDM, headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.</p>
<div class="lb-trans"><p>Tandem Diabetes Care, Inc NASDAQ: TNDM，總部位於加利福尼亞州聖地亞哥，是一家醫療設備公司，專注於為胰島素依賴型糖尿病患者設計、開發和商業化創新的胰島素輸送系統。公司成立於 2006 年，2011 年推出了首款產品 t:slim® 胰島素泵，並自此建立了一個包含觸摸屏界面、遠程軟件更新和集成連續血糖監測（CGM）功能的下一代泵的產品組合。</p>
</div><p>The company's flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.</p>
<div class="lb-trans"><p>該公司的旗艦產品 t:slim X2® 胰島素泵，旨在與領先的 CGM 傳感器配合使用，並具有根據實時血糖趨勢調整基礎胰島素速率的自動胰島素輸送算法。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Tandem Diabetes Care</li>
<li>The gold chart Wall Street is terrified of…</li>
<li>America’s 1776 happening again</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票比 Tandem Diabetes Care 更好</li>
<li>華爾街害怕的黃金圖表……</li>
<li>美國的 1776 再次發生</li>
<li>在 2026 年 5 月之前購買這隻黃金股票</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
<li>用這 4 個簡單步驟 &#34;防止美聯儲影響&#34; 你的銀行賬户</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5ETQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=TNDM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Tandem Diabetes Care Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Tandem Diabetes Care 嗎？</h2>
</div><p>Before you consider Tandem Diabetes Care, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Tandem Diabetes Care 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tandem Diabetes Care wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及他們推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Tandem Diabetes Care 並不在名單上。</p>
</div><p>While Tandem Diabetes Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然分析師目前對 Tandem Diabetes Care 的評級為持有，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Royce & Associates LP Makes New Investment in Tandem Diabetes Care, Inc. $TNDM

Market Beat

Tandem Diabetes

Royce & Associates LP 對 Tandem Diabetes Care, Inc. $TNDM 進行了新的投資